Brexit Good For UK Firms And Emerging Markets?
This article was originally published in PharmAsia News
Despite creating shockwaves around the globe, the UK’s ‘Brexit’ vote to leave the EU is expected by analysts to positively impact European pharma companies such as GSK, Sanofi and AstraZeneca. But the impact on product sales and emerging markets will be more of a mixed bag.
You may also be interested in...
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.